Jolimont, Belgium, 27. August 2024 – Jolimont Hospital, a flagship institution within the HELORA network, has successfully implemented the AI-powered clinical care coordination platform PMcardio to optimize the detection and management of acute myocardial infarction, specifically ST-elevation myocardial infarction (STEMI) and STEMI-equivalent patterns. This cutting-edge initiative marks Jolimont as the first hospital in the Wallonia Region and the second in Belgium, following Cardiovascular Center Aalst, OLV Hospital, to augment the chest pain patient pathway using artificial intelligence.
The hospital has introduced the CE-certified ECG interpretation platform, which enables timely and accurate detection of STEMI or its equivalents from a single ECG at the first point of contact. Due to their subtle presentation on ECGs, up to 40% of AMI patients are initially misdiagnosed. This leads to delays in accurate diagnosis and timely management of this life-threatening condition.
With this AI implementation, all healthcare professionals at Jolimont—across emergency, intensive care, cardiology, and internal medicine units—are thoroughly trained to utilize the PMcardio platform to ensure a seamless chest pain patient journey. This comprehensive approach ensures that any patient suspected of having an acute myocardial infarction receives timely detection and treatment.
Dr. Jean-Christophe Reuters, interventional cardiologist at Jolimont HELORA Hospital, emphasized the institution’s commitment to innovation: “Integrating cutting-edge technology into clinical practice is not just an option; it is a priority for Jolimont. By embracing the latest AI innovations like PMcardio, we are reinforcing our commitment to excellence and ensuring that our patients benefit from the most advanced medical care available.”
The model’s performance has been rigorously evaluated and compared to conventional STEMI criteria and expert ECG assessments, showing a remarkable area under the curve (AUC) of 0.938 for identifying occlusion myocardial infarction, with an accuracy of 90.9%, sensitivity of 80.6%, and specificity of 93.7%. These results were published in the European Heart Journal – Digital Health, where it still remains the most-read publication after eight months of publishing, underscoring the significant interest and recognition this research has garnered for its effectiveness in detecting acute occlusive myocardial infarction.
“We are proud that the Jolimont Hospital adopted our AI technology into clinical practice, to combat the leading cause of mortality worldwide. The impact of this technology extends beyond the immediate treatment of acute coronary syndrome; early detection and timely management significantly contribute to a better long-term prognosis for patients.”, said Dr. Robert Herman, Chief Medical Officer at Powerful Medical, the medical device manufacturer behind PMcardio.
Time to intervention is the number one predictor of long-term prognosis in acute myocardial infarction patients. By timely detection at the first point of patient contact, AI can
Following the successful launch at Jolimont, plans are underway to extend the PMcardio platform across other institutions within the HELORA network, further enhancing cardiac care for patients across the region.
About Jolimont Hospital Jolimont Hospital is a key member of the HELORA network, dedicated to providing exceptional healthcare services in Belgium. With a focus on innovation and patient-centered care, Jolimont continually seeks to implement the latest advancements in medical technology to improve patient outcomes.
